MedTrace Logo

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2025-09-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Conditions

  • Nasal Polyps

Interventions

BIOLOGICAL

Depemokimab (GSK3511294)

Depemokimab (GSK3511294) was administered using a pre-filled syringe.

DRUG

Placebo

Placebo was administered as normal saline using a pre-filled syringe.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-18
Primary Completion
2024-07-12
Completion
2024-08-06
FDA Drug
Yes

Countries

  • United States
  • China
  • Italy
  • Japan
  • Poland
  • Romania
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05281523 on ClinicalTrials.gov